TopoTarget soars as ProStrakan slashed by 25%

Shares in TopoTarget, a Danish biotechnology company, soared by a fifth after it started trading this morning. UK rival ProStrakan, by contrast, today cut the reduced price of its initial public offering by a further 25%.

ABN Amro Rothschild/Alfred Berg, Danske Markets and Handelsbanken Capital Markets led the Dkr225m (€30m) TopoTarget offer which is the first flotation in Denmark for four years.

WSJ Logo
Pro Bono or Pro Nono? Law Firms Split on Fulfilling Deals With TrumpExternal link

Pro Bono or Pro Nono? Law Firms Split on Fulfilling Deals With Trump